Drug Prices Post Biggest Yearly Drop Since 1963. Trump Claims Credit, Economists Point Elsewhere

Prescription drug prices dropped 0.8% in July and are down 3.1% from a year ago, according to Consumer Price Index data from the Bureau of Labor Statistics. That's the sharpest year-over-year decline since 1963.

President Trump wants credit for it. The White House says the drop proves his "most favored nation" pricing deals with drugmakers and the new TrumpRx website are working, calling the results proof the policies are "delivering real relief to American families and putting patients first."

Trump made sure everyone saw it. According to the Guardian, he staged a photo-op Friday holding up a printed Washington Post headline reading "Prescription drug prices record sharpest drop in more than 60 years," telling reporters, "I told you that was going to happen," before the White House posted the image with the caption "POV: you bring the receipts."

There's a problem with that victory lap. The Guardian reports the Washington Post article Trump was holding up actually quoted experts crediting a different president's policy. Richard Frank, a professor emeritus of health economics at Harvard, told the Post that if he had to bet on what's driving the decline, "it would be probably stuff around the Inflation Reduction Act" — Joe Biden's 2022 law — adding that Trump's efforts "wouldn't be where I'd place my money."

What the law actually does

The Inflation Reduction Act let Medicare negotiate prices directly with drugmakers for the first time, something the program had been barred from doing for years. The first batch of negotiated prices for 10 top-selling drugs took effect in January 2026, according to the Associated Press, MedPage Today, and PBS.

Three independent health policy researchers cited across multiple outlets — Juliette Cubanski of KFF, Dr. Benjamin Rome of Harvard Medical School, and Stacie Dusetzina of Vanderbilt — all said those newly negotiated prices likely moved the aggregate numbers. Cubanski put it bluntly: "It's difficult to know in one number what's going on beneath the hood. I don't think we can attribute this price reduction to any one specific policy change or initiative."

Competition is doing real work too

It's not just Medicare negotiation. Rome told the AP that "when big blockbuster products face generic competition, their prices fall," pointing to biosimilar versions of Humira that have hit the market treating the same autoimmune conditions at lower cost. Dusetzina noted a similar pattern with Stelara, a biologic used for chronic inflammatory conditions, where new competitors have pushed prices down.

None of this is really about what a patient pays at the pharmacy counter, either. The CPI drug price index measures what pharmacies get paid by insurers and consumers combined, not out-of-pocket costs. As PBS and MedPage Today both note, that's a wonky technical distinction that gets lost when a president waves around a headline.

The Trump administration's actual case

The White House isn't inventing its policies out of thin air. The "most favored nation" deals struck with pharmaceutical companies and the TrumpRx platform, launched with CMS Administrator Mehmet Oz, are real agreements that did produce some negotiated discounts, and the administration argues those deals are just now beginning to show up in list prices. The administration also has carried forward the Biden-era Medicare negotiations as required by law and projects additional savings in coming years, which the AP and MedPage Today both confirm — meaning Trump officials aren't rejecting the IRA framework, they're operating it and layering their own deals on top.

That's a legitimate point: multiple policies overlapping in the same data makes it hard to isolate which one is doing the heavy lifting, a fact even the harshest critics like Cubanski acknowledge. This isn't a case of Trump inventing a policy from nothing — it's a case of him claiming sole credit for a multi-year, multi-administration trend with several moving parts.

Breitbart's coverage leans hardest into the "Trump Effect" framing, citing Renaissance Macro data that prescription drug prices have fallen at an annualized rate of 6.6% over the last six months, calling it the sharpest drop on record. That's an accurate number, but Breitbart's piece doesn't mention the Inflation Reduction Act, the Medicare negotiations, or any of the economists who say those Biden-era policies are the more likely driver — an omission every other outlet in this batch flagged as central to the story.

The Guardian's framing runs the opposite direction, built almost entirely around mocking Trump's photo-op rather than the underlying economics, though it does accurately quote Frank and the Post's original reporting.

What's unresolved

No study cited in any of these reports isolates how much of the 3.1% drop comes from IRA negotiations versus generic competition versus Trump's MFN deals. Cubanski's answer stands: nobody can currently break out the number "beneath the hood." The CPI report that triggered all of this was released by the Bureau of Labor Statistics last week, and additional negotiated Medicare drug prices are scheduled to phase in over the next several years under the law's existing timeline, giving future CPI reports more data points to help sort out which policy is actually doing what.